Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients

Circulation Journal

Volumn 77, Issue 5, 2013, Pages 1208-1213

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Minatsuki, Shun ^a   Muraoka, Hironori ^a   Kato, Naoko ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Shiga, Taro ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Kyo, Shunei ^a   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Hyponatremia; Responder; Vasopressin

Indexed keywords

CREATININE; SODIUM; TOLVAPTAN;

ADULT; AGED; ARTICLE; CHEMICAL ANALYSIS; FEMALE; FLUID RETENTION; HEART FAILURE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; UREA NITROGEN BLOOD LEVEL; URINALYSIS; URINE OSMOLALITY; URINE VOLUME;

AGED; AGED, 80 AND OVER; BENZAZEPINES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CREATININE; FEMALE; HEART FAILURE; HORMONE ANTAGONISTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NITROGEN; OSMOLAR CONCENTRATION; RECEPTORS, VASOPRESSIN; RETROSPECTIVE STUDIES; SODIUM; TIME FACTORS; TREATMENT OUTCOME; UREA;

EID: 84876774205     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1328     Document Type: Article

References (29)

1. Kinugawa K. How to treat stage D heart failure? When to implant left ventricular assist devices in the era of continuous flow pumps? Circ J 2011; 75: 2038-2045.
2. Sata Y, Krum H. The future of pharmacological therapy for heart failure. Circ J May 2010; 74: 809-817.
3. Greenberg B. Acute decompensated heart failure: Treatments and challenges. Circ J 2012; 76: 532-543.
4. Arao K, Fujiwara T, Sakakura K, Wada H, Sugawara Y, Suga C, et al. Hyponatremia as a predictor for worsening heart failure in patients receiving cardiac resynchronization therapy. Circ J 2013; 77: 116-122.
5. O'Connell JB, Alemayehu A. Hyponatremia, heart failure, and the role of tolvaptan. Postgrad Med 2012; 124: 29-39.
6. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
7. Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, place-bo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-1545.
8. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
9. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25 (Suppl 1): S33-S45.
10. Imamura T, Kinugawa K, Shiga T, Kato N, Endo M, Inaba T, et al. Correction of hyponatremia by tolvaptan before left ventricular assist device implantation. Int Heart J 2012; 53: 391-393.
11. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011; 7: 151-161.
12. Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: Association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.
13. Mozolowski W. Chemical composition of normal urine. Lancet 1948; 1: 423.
14. Purssell RA, Pudek M, Brubacher J, Abu-Laban RB. Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap. Ann Emerg Med 2001; 38: 653-659.
15. Kim GH, Han JS, Kim YS, Joo KW, Kim S, Lee JS. Evaluation of urine acidification by urine anion gap and urine osmolal gap in chronic metabolic acidosis. Am J Kidney Dis 1996; 27: 42-47.
16. Leech S, Penney MD. Correlation of specific gravity and osmolality of urine in neonates and adults. Arch Dis Child 1987; 62: 671-673.
17. Imran S, Eva G, Christopher S, Flynn E, Henner D. Is specific gravity a good estimate of urine osmolality? J Clin Lab Anal 2010; 24: 426-430.
18. Voinescu GC, Shoemaker M, Moore H, Khanna R, Nolph KD. The relationship between urine osmolality and specific gravity. Am J Med Sci 2002; 323: 39-42.
19. Kwon TH, Frokiaer J, Knepper MA, Nielsen S. Reduced AQP1, -2, and -3 levels in kidneys of rats with CRF induced by surgical reduction in renal mass. Am J Physiol 1998; 275(5 Pt 2): F724-F741.
20. Teitelbaum I, Mcguinness S. Vasopressin resistance in chronic-renal-failure: Evidence for the role of decreased V-2 receptor messenger-RNA. J Clin Invest 1995; 96: 378-385.
21. Bedford JJ, Leader JP, Walker RJ. Aquaporin expression in normal human kidney and in renal disease. J Am Soc Nephrol 2003; 14: 2581-2587.
22. Kleeman CR, Adams DA, Maxwell MH. An evaluation of maximal water diuresis in chronic renal disease. I: Normal solute intake. J Lab Clin Med 1961; 58: 169-184.
23. Purssell RA, Lynd LD, Koga Y. The use of the osmole gap as a screening test for the presence of exogenous substances. Toxicol Rev 2004; 23: 189-202.
24. Kamel KS, Ethier JH, Richardson RM, Bear RA, Halperin ML. Urine electrolytes and osmolality: When and how to use them. Am J Nephrol 1990; 10: 89-102.
25. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25(Suppl 1): S57-S65.
26. Dabrowska MD, Krysiak R, Okopien B. Hyponatremic hypervolemia in heart failure-the hot spot for vasopressin receptor antagonists? Wiad Lek 2012; 65: 19-30 (in Polish).
27. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56: 1527-1534.
28. Blanchard A, Frank M, Wuerzner G, Peyrard S, Bankir L, Jeunemaitre X, et al. Antinatriuretic effect of vasopressin in humans is amiloride sensitive, thus ENaC dependent. Clin J Am Soc Nephrol 2011; 6: 753-759.
29. Mironova E, Bugaj V, Roos KP, Kohan DE, Stockand JD. Aldosterone-independent regulation of the epithelial Na+ channel (ENaC) by vasopressin in adrenalectomized mice. Proc Natl Acad Sci USA 2012; 109: 10095-10100.